Skip to main content
. 2013 Jul 18;109(3):589–596. doi: 10.1038/bjc.2013.367

Table 5. Comparison of adverse events between BMI categories stratified by treatment.

  Control
Anastrozole
 
 
Norm (n=87)
Over (n=253)
Norm (n=90)
Over (n=204)
 
Adverse event N % N % N % N % P-value
Allergy
1
1.1
1
0.4
3
3.3
5
2.5
0.467
Amenorrhoea
85
97.7
245
96.8
84
93.3
192
94.1
0.976
Arrhythmia
3
3.4
3
1.2
4
4.4
8
3.9
0.344
Asthenia
3
3.4
2
0.8
5
5.6
9
4.4
0.211
Bleeding
1
1.1
1
0.4
2
2.2
1
0.5
0.119
Bone aches
25
28.7
50
19.8
26
28.9
57
27.9
0.190
Card disorders
5
5.7
17
6.7
2
2.2
13
6.4
0.222
Cutaneous toxicity
0
0.0
1
0.4
6
6.7
10
4.9
0.647
Depressions
10
11.5
21
8.3
17
18.9
33
16.2
0.319
Diarrhoea
3
3.4
7
2.8
5
5.6
12
5.9
0.918
Eczema
1
1.1
6
2.4
1
1.1
12
5.9
0.058
Fever
1
1.1
4
1.6
3
3.3
5
2.5
0.866
Headache
10
11.5
30
11.9
20
22.2
44
21.6
0.967
Haematuria
0
0.0
2
0.8
1
1.1
3
1.5
0.505
Hair loss
1
1.1
8
3.2
12
13.3
20
9.8
0.746
Hot flushes
18
20.7
61
24.1
42
46.7
82
40.2
0.725
Infections
2
2.3
6
2.4
5
5.6
9
4.4
0.749
Nausea
2
2.3
6
2.4
9
10.0
13
6.4
0.358
Obstipation
2
2.3
9
3.6
8
8.9
14
6.9
0.858
Pericarditis
0
0.0
0
0.0
1
1.1
0
0.0
0.132
Proteinuria
0
0.0
1
0.4
1
1.1
1
0.5
0.866
Somnolence
4
4.6
12
4.7
9
10.0
26
12.7
0.557
Vaginal discharge
6
6.9
5
2.0
5
5.6
16
7.8
0.480
Vaginal dryness
11
12.6
20
7.9
16
17.8
23
11.3
0.045
Vomiting
2
2.3
5
2.0
3
3.3
5
2.5
0.659
Other 28 32.2 82 32.4 42 46.7 78 38.2 0.345

Abbreviation: BMI=body mass index.